Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Penwest Provides Results Of Phase Ib Trial Of A0001
Penwest has provided the results of its phase Ib clinical trial of A0001, for the treatment of mitochondrial diseases. The phase Ib trial was a single-blind, placebo-controlled, multiple
Penwest has provided the results of its phase Ib clinical trial of A0001, for the treatment of mitochondrial diseases. The phase Ib trial was a single-blind, placebo-controlled, multiple
Novartis has reported a 12% decrease in net income to $4 billion, for the first half of 2009. The decline was also impacted by financing costs incurred due
ViRexx has received a contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This 14-month project will focus on the development of bio-nanoparticle-based siRNA
Ipsen has announced the results of phase I and phase IIa clinical studies for BIM23A760, designed and developed by its peptide engineering platform. This molecule targets two patho-physiological
German Merck has received approval from Japanese Ministry of Health, Labor and Welfare to extend indication of Gonal-f (follitropin alfa for injection). It is for infertile women suffering
Adeona has provided results of a 90 subject prospective, blinded, observational clinical study to evaluate copper and zinc status in Alzheimer’s disease, Parkinson’s disease and normal subjects. The
Tibotec Pharmaceuticals has entered into an agreement with Gilead Sciences for the development and commercialization of a new, once-daily fixed-dose antiretroviral product. It contains Tibotec’s investigational non-nucleoside reverse
Reliv International’s GlucAffect, a nutritional supplement, seems to be effective in reducing blood glucose levels and control weight in study participants. The study included 50 overweight individuals who
Yara International has reported second-quarter net income of NOK1.12 billion, as compared to NOK4.35 billion last year. Excluding net foreign exchange gains and special items, the result was
American Medical (AMS), a provider of medical solutions for restoring men’s and women’s pelvic health, has announced that its AMS 700 with INHIBIZONE has been approved by the